BioLineRx Ltd. (BLRX) Sees Significant Decrease in Short Interest
BioLineRx Ltd. (NASDAQ:BLRX) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totalling 384,624 shares, a decline of 52.2% from the August 15th total of 804,376 shares. Based on an average trading volume of 360,841 shares, the short-interest ratio is currently 1.1 days.
Several hedge funds have recently added to or reduced their stakes in BLRX. Citadel Advisors LLC boosted its position in shares of BioLineRx by 443.4% during the 1st quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 86,481 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of BioLineRx during the 1st quarter worth about $126,000. KCG Holdings Inc. boosted its position in shares of BioLineRx by 715.9% during the 1st quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 153,687 shares in the last quarter. Finally, Sabby Management LLC bought a new position in shares of BioLineRx during the 1st quarter worth about $3,018,000. 32.27% of the stock is currently owned by institutional investors.
Shares of BioLineRx (BLRX) opened at 1.07 on Tuesday. BioLineRx has a 1-year low of $0.80 and a 1-year high of $1.42. The firm’s market cap is $102.31 million. The firm has a 50 day moving average price of $1.08 and a 200 day moving average price of $0.96.
BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.05). Analysts anticipate that BioLineRx will post ($0.24) EPS for the current year.
BLRX has been the topic of several recent analyst reports. ValuEngine upgraded BioLineRx from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Roth Capital initiated coverage on BioLineRx in a report on Thursday, August 3rd. They set a “buy” rating and a $3.00 target price on the stock. Zacks Investment Research lowered BioLineRx from a “buy” rating to a “sell” rating in a report on Tuesday, June 20th. Maxim Group set a $3.00 target price on BioLineRx and gave the stock a “buy” rating in a report on Tuesday, August 8th. Finally, HC Wainwright set a $4.00 target price on BioLineRx and gave the stock a “buy” rating in a report on Saturday, June 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. BioLineRx has a consensus rating of “Buy” and an average price target of $2.59.
BioLineRx Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.